Frank Gansauge1,2* and Bertram Poch1
1Center for Oncologic, Endocrine and Minimal-Invasive Surgery, Germany
2LDG - Laboratories Dr. Gansauge - GmbH, Germany
Introduction: Even after surgical resection and multimodal treatment in gastric cancer the 5-year Disease Free Survival times (DFS) as well as Overall Survival rates (OS) are still below one third of the patients. Here we retrospectively analyzed the outcome of immunotherapy in the additional adjuvant treatment of gastric cancer with Long Antigen Exposition Dendritic Cell therapy (LANEXDC ®) in 16 patients who were treated at our institution (intent-to- treat-analysis).
Patients: Data were available of 16 patients. Dendritic Cells (LAEX-DC®) were produced according to a recently published protocol.
Results: Therapy was well tolerated and no serious side effects were observed. Five year DFS and OS were 62.5% and 67.5%. Interestingly, two of the patients developed recurrence of the disease more than 7 years following resection for gastric cancer.
Conclusion: We were able to show in a small cohort of patients that additional treatment with dendritic cells (LANEX-DC®) is highly effective and extends the DFS and OS in the adjuvant treatment of gastric cancer.
Gastric cancer; Dendritic cells; LANEX-DC®; Immunotherapy; Adjuvant
Gansauge F, Poch B. Effectivity of Long Antigen Exposition Dendritic Cell Therapy (LANEX-DC®) in the Adjuvant Treatment of Gastric Cancer. Clin Oncol. 2022;7:1929..